- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | Cinclus Pharma Holding AB: Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US - Positive for the Company's Phase III Program | 138 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for acid-related gastrointestinal diseases, today announces that the FDA has clarified... ► Artikel lesen | |
| 18.02. | Cinclus Pharma Holding AB: Year-end report - Advancing toward Phase III readout | 103 | GlobeNewswire (Europe) | "The past year was marked by significant progress for Cinclus Pharma. Our first Phase III study has had a promising start, and we expect to present topline results during the second half of the year.... ► Artikel lesen | |
| CINCLUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.02. | Cinclus Pharma Holding AB: Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA | 101 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced that the US Food and Drug Administration... ► Artikel lesen | |
| 10.02. | Cinclus Pharma Holding AB: Cinclus Pharma receives regulatory support - EMA provides positive feedback on CMC for linaprazan glurate | 100 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced that the European Medicines Agency... ► Artikel lesen | |
| 19.01. | Cinclus Pharma Holding AB: Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026 | 366 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ) (Reg. No. 559136-8765) today, on 19 January 2026, held an Extraordinary General Meeting.The Extraordinary General Meeting resolved, in accordance with the Nomination... ► Artikel lesen | |
| 08.12.25 | Cinclus Pharma Holding AB: Cinclus Pharma recruits Magnus Christensen as new CFO | 235 | GlobeNewswire (Europe) | Cinclus Pharma today announces that Magnus Christensen has been recruited as CFO after Maria Engström, at her own request, has chosen to leave her role. He comes most recently from a role as CFO at... ► Artikel lesen | |
| 20.11.25 | Cinclus Pharma Q3 2025: Fortschritte in Phase-3-Studie bei anhaltend hohen F&E-Investitionen | 2 | Investing.com Deutsch | ||
| 20.11.25 | Cinclus Pharma Q3 2025 slides: Phase 3 trial progress amid continued R&D investment | 1 | Investing.com | ||
| 20.11.25 | Cinclus Pharma Holding AB: A positive start to the Phase III study | 165 | GlobeNewswire (Europe) | "Cinclus Pharma has now entered late-stage clinical development following the initiation of its first Phase III study, and patient recruitment has so far progressed well. Topline results are expected... ► Artikel lesen | |
| 07.10.25 | Cinclus Pharma Holding AB: Cinclus Pharma doses first patient in Phase III study evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease | 133 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing the next-generation treatments for acid-related diseases, today announced that the first patient has been dosed... ► Artikel lesen | |
| 12.09.25 | Cinclus Pharma Holding AB: Cinclus Pharma announces screening of first patient in HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive GERD | 237 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for acid-related diseases, today announced the screening of the first patient with... ► Artikel lesen | |
| 29.08.25 | Cinclus Pharma Holding AB: Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD) | 472 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing the next generation of treatments for acid-related diseases, today announced the initiation of its Phase III HEEALING... ► Artikel lesen | |
| 20.08.25 | Cinclus Pharma Holding AB: Interim report January-June 2025 - Strengthened position for future value creation | 271 | GlobeNewswire (Europe) | "Our recently announced partnership with Zentiva k.s. for commercialization and manufacturing in Europe is a strong validation of both our product and strategic direction. This collaboration lays the... ► Artikel lesen | |
| 16.06.25 | Cinclus Pharma Holding AB: Cinclus Pharma secures EMA and FDA pediatric study waivers for linaprazan glurate in H. pylori infection | 232 | GlobeNewswire (Europe) | Cinclus Pharma AB (publ), a clinical-stage pharmaceutical company developing next generation treatments for acid-related diseases, today announced that the European Medicines Agency (EMA) and the US... ► Artikel lesen | |
| 20.05.25 | Cinclus Pharma Holding AB: Interim report January-March 2025 | 336 | GlobeNewswire (Europe) | "In parallel with the preparations for the Phase III study, we are strengthening our presence and visibility in academia and the medical profession and intensifying the work for an upcoming commercialization.... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CSPC PHARMA | 0,934 | +1,52 % | CSPC PHARMA Extends Gains to ~3%; 2025 Rev. Drops 10.4%, but Final DPS Added | ||
| BACHEM | 70,65 | +2,32 % | Bachem FY25 Earnings Rise; Proposes Dividend Increase; Guides FY26 | WASHINGTON (dpa-AFX) - Bachem Holding AG (BCHMY, BCHMF), a Swiss biotechnology company, on Thursday reported higher full-year 2025 net income compared with the previous year, proposed a dividend... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,345 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 59,50 | +0,57 % | BridgeBio Pharma, Inc.: BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions | ||
| OPUS GENETICS | 3,815 | -1,93 % | Opus Genetics, Inc.: Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | ||
| ONO PHARMACEUTICAL | 13,300 | +0,76 % | Ono Pharmaceutical Co. Ltd. Reveals Climb In Nine Months Bottom Line | TOKYO (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF) released a profit for its nine months that Increases, from the same period last yearThe company's earnings came in at JPY68.949 billion... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 2,760 | +10,40 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results | Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 10,000 | -2,91 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel | ||
| BAYER | 38,400 | +1,75 % | BAYER mit neuem Rückenwind | Auslöser waren Analystenempfehlungen und positive Studiendaten zum Nierenmittel "Kerendia". UBS sieht mit einem Kursziel von 52 € weiteres Potenzial über das bisherige Jahreshoch hinaus. Man hebt das... ► Artikel lesen | |
| MERCK KGAA | 105,85 | +2,42 % | EQS-DD: Merck KGaA: Belén Garijo Lopez, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.03.2026 / 10:59... ► Artikel lesen | |
| NOVO NORDISK | 31,920 | -0,08 % | Milliardenmarkt vor Umbruch: Angriff auf Eli Lilly und Novo Nordisk: Roche wittert Milliardenchance | © Foto: Udo Herrmann - picture alliance / CHROMORANGERoche will im boomenden Markt für Abnehm-Medikamente wieder angreifen. Der Konzern setzt auf neue Strategien und Milliarden-Deals im Wettbewerb.Der... ► Artikel lesen | |
| GSK | 23,440 | +2,76 % | BARCLAYS stuft GSK auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für GSK mit einem Kursziel von 1900 Pence auf "Underweight" belassen. Jüngste Absatzdaten belegten auf Wochensicht... ► Artikel lesen | |
| DERMAPHARM | 42,550 | +1,79 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| ASTRAZENECA | 161,55 | +0,72 % | Hacker stehlen AstraZeneca-Quellcode | ||
| PFIZER | 23,350 | +0,30 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen |
Das Unternehmen CINCLUS PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,486 Euro und damit -5,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CINCLUS PHARMA HOLDING AB finden Sie auf Wallstreet Online.